Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibudilast in ALS
NCT02238626Phase 2Completed
- Sponsor
- MediciNova, Inc.
- Start
- Sep 2014
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibudilast in amyotrophic lateral sclerosis (ALS), sponsored by MediciNova, Inc.. Started Sep 2014; status: completed.
02
Drugs
ibudilast
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02238626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02238626.